For best experience please turn on javascript and use a modern browser!
Bekijk de site in het Nederlands

Minimal residual disease (MRD) is the term used to describe small numbers of tumour cells remaining in blood or bone marrow during or after treatment which are below the limits of detection using morphological assessment. Bone marrow metastases are frequently found in neuroblastoma patients. In her research, Esther van Wezel focuses on improving detection and investigates the clinical significance of MRD detection in different stages of treatment.

Event details of Detection of residual tumour cells in bone marrow
Date 28 April 2016
Time 12:00 -13:00
Location Agnietenkapel
Room Location

E.M. van Wezel: Minimal Residual Disease Monitoring in Neuroblastoma.

Supervisors

Prof. C.E. van der Schoot

Prof. H.N. Caron

Co-supervisor

Dr G.A.M. Tytgat

Agnietenkapel

Room Location

Oudezijds Voorburgwal 229 - 231
1012 EZ Amsterdam

Entrance

This event is open to the public.